The invention heart failure (particularly, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome growth factor-activated receptor (PPAR) gamma agonists - fluid retention, or salts, such as the induced fluid retention It relates to compounds and methods for treating disorders associated with the overload. The invention also relates to compounds and methods for the treatment of high blood pressure. The invention also relates to containing the treatment or reduction of pain associated with gastrointestinal dysfunction, compounds and methods for the treatment of gastrointestinal disorders. The method, in general, necessary to mammalian gastrointestinal (GI) of the tube that sodium ions and hydrogen ions in the in the NHE- that are designed to be substantially active in inhibiting mediated yeoksusong compound or pharmaceutical composition comprising such a compound of it comprise administering a pharmaceutically effective amount. More particularly, the method comprising inhibiting a mammal in need of a sodium ion and NHE-3, -2 and / or -8-mediated yeoksusong of hydrogen ions in the GI tract, and the epithelial cell layer, and more particularly the epithelial layer of the GI tract in a substantially light comprises administering a pharmaceutically effective amount of a pharmaceutical composition comprising a compound or compounds of these designs such that the transmissivity. To the compound is substantially impermeable result, this is not absorbed, and thus other internal organs essentially a non-systemic exposure that is limited (e. G., Liver, heart, brain, etc.) thereof-is bioavailability. How to provide the capability to act as by administration with the water absorbent polymer discussed the combination described above, and further isolate the fluid and / or salt present in the GI tract - the present invention also provides such a compound to a mammal fluid It relates.본 발명은 심부전 (특히, 울혈성 심부전), 만성 신장질환, 말기 신장 질환, 간 질환,
